Baird Medical Accelerates Global Registration of AI-Driven Surgical Software

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) announced completion of development for its cross-platform, AI-driven surgical software and has begun regulatory registration in the United States, European Union, and China on March 4, 2026. The system automates anatomical mapping, dynamic treatment planning, and procedural simulations using a proprietary AI model.

The software integrates diverse diagnostic imaging and is engineered to connect with Baird Medical's upcoming automated surgical robotic system, aiming to create a closed-loop surgical ecosystem spanning pre-, intra- and post-operative workflows and to accelerate the company's commercial roadmap.

Key Figures

Warrant shares registered: 11,500,000 shares Resale shares registered: 34,415,562 shares Warrant exercise price: US$11.50 per share +5 more

8 metrics

Warrant shares registered 11,500,000 shares Ordinary shares issuable upon exercise of public warrants at US$11.50

Resale shares registered 34,415,562 shares Ordinary shares registered for resale by existing shareholders

Warrant exercise price US$11.50 per share Exercise price for public warrants

Reference share price US$1.63 per share Nasdaq share price on December 4, 2025 vs warrant exercise price

Resale ownership share 70.9% Assumed resale shares plus conversions as % of shares outstanding

Current share price $2.52 Price before AI software registration news

Daily price change -11.39% 24-hour move prior to publication

Market capitalization $103,199,776 Equity value based on pre-news share price

Market Reality Check

Price: $2.52 Vol: Volume 2,294,602 is below...

low vol

$2.52 Last Close

Volume Volume 2,294,602 is below 20-day average 5,021,974, indicating muted trading interest pre-announcement. low

Technical Trading above 200-day MA of 2.33 with price at 2.52, after a -11.39% daily decline.

Peers on Argus

BDMD fell 11.39% while peers were mixed: ICAD +3.48%, XTNT +3.26%, APYX -0.31%, ...

1 Down

BDMD fell 11.39% while peers were mixed: ICAD +3.48%, XTNT +3.26%, APYX -0.31%, ICCM -1.4%, NSPR -5.03%. Momentum scanner shows LUCD down 3.45%, supporting a stock-specific move for BDMD.

Previous AI Reports

2 past events · Latest: Mar 24 (Positive)

Same Type Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Mar 24	AI award recognition	Positive	-1.6%	Robot won an investment award highlighting AI-driven tumor ablation leadership.
Mar 17	AI award recognition	Positive	-1.6%	Award for AI surgical robot integrating multimodal algorithms and robotic control.

Pattern Detected

AI-tagged announcements previously showed modest negative reactions around -1.6% despite positive thematic news.

Recent Company History

Over the past year, AI-tagged news for Baird Medical focused on its AI Tumor Ablation Surgical Robot receiving a "Most Valuable Investment Award" and highlighting leadership in AI-driven tumor ablation. Those announcements on Mar 17 and Mar 24, 2025 were positive in tone but saw mild share declines of -1.65% and -1.56%. Today’s AI-driven surgical software registration continues this theme of expanding an AI-enabled surgical ecosystem, but against a much larger pre-news drop.

Historical Comparison

-1.6% avg move · Past AI-tag news for BDMD saw small declines averaging -1.6%. Today’s -11.39% pre-announcement drop ...

AI

-1.6%

Average Historical Move AI

Past AI-tag news for BDMD saw small declines averaging -1.6%. Today’s -11.39% pre-announcement drop represents a much larger downside move than prior AI-related headlines.

Prior AI news centered on an award-winning AI surgical robot. The current update advances this roadmap with cross-platform AI surgical software designed to integrate into a fully automated robotic system, moving from recognition to concrete product registration across major geographies.

Market Pulse Summary

This announcement highlights completion of development for cross-platform, AI-driven surgical softwa...

Analysis

This announcement highlights completion of development for cross-platform, AI-driven surgical software and the start of registration in the U.S., EU, and China. The system is designed to automate anatomical mapping, treatment planning, and simulations, and to integrate with an upcoming fully automated surgical robotic platform, forming a closed-loop ecosystem. Historically, AI-related news for Baird Medical has produced only modest share moves around -1.6%, while recent filings emphasize potential selling overhang and China regulatory risks.

Key Terms

microwave ablation (MWA), artificial intelligence, surgical robotic system

3 terms

microwave ablation (MWA) medical

"a market leader in minimally invasive Microwave Ablation (MWA) technology"

Microwave ablation (MWA) is a minimally invasive medical procedure that uses focused microwave energy to heat and destroy unwanted tissue, such as tumors or lesions, without open surgery. Think of it like using a tiny, precise microwave oven inside the body to remove a problem area; for investors, MWA matters because its effectiveness, safety, costs, and adoption influence demand for related devices, hospital procedures, reimbursement and potential market growth.

artificial intelligence technical

"Leveraging a proprietary artificial intelligence model, the system automates core clinical workflows"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

surgical robotic system technical

"integrate directly with Baird Medical's upcoming non-invasive and minimally invasive fully automated surgical robotic system"

A surgical robotic system is a hospital-grade machine that combines robotic arms, high-resolution cameras and control software to help surgeons perform operations with smaller cuts, steadier movements and better views. Investors care because these systems can change how often and how profitably procedures are done: hospitals buy expensive equipment, pay ongoing fees for instruments and service, and may attract more patients, making adoption, approvals and recurring revenue important signals of financial upside.

AI-generated analysis. Not financial advice.

NEW YORK, March 4, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful completion of development for its cross-platform surgical software, officially commencing the registration process in the United States, the European Union, and China.

Leveraging a proprietary artificial intelligence model, the system automates core clinical workflows, including anatomical mapping, dynamic treatment planning, and procedural simulations. By integrating diverse diagnostic imaging, the software assists physicians in defining precise surgical pathways and parameters, designed to optimize patient outcomes across a broad spectrum of minimally invasive modalities.

This digital infrastructure is engineered to integrate directly with Baird Medical's upcoming non-invasive and minimally invasive fully automated surgical robotic system. This integration establishes a comprehensive, closed-loop surgical ecosystem, which spans pre-operative analysis and decision-making, intra-operative execution, and post-operative evaluation. This evolution accelerates the Company's commercial roadmap and addresses the increasing global demand for highly integrated, intelligent interventional ecosystems.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-accelerates-global-registration-of-ai-driven-surgical-software-302703622.html

SOURCE BDMD

FAQ

What did Baird Medical (BDMD) announce on March 4, 2026 about its AI surgical software?

Baird Medical announced completion of development and the start of registration in the US, EU, and China. According to the company, the cross-platform software automates mapping, planning, and simulations and integrates imaging to support minimally invasive procedures.

How will BDMD's AI-driven software integrate with the company's robotic system?

The software is engineered to integrate directly with Baird Medical's upcoming automated surgical robot, creating a closed-loop ecosystem. According to the company, this spans pre-operative analysis, intra-operative execution, and post-operative evaluation.

What clinical workflows does Baird Medical's new software automate for BDMD?

The system automates anatomical mapping, dynamic treatment planning, and procedural simulations to assist physicians. According to the company, it combines diverse diagnostic imaging to define precise surgical pathways and parameters.

Which markets has BDMD begun registering the AI surgical software in and when?

Baird Medical has commenced registration in the United States, European Union, and China as of March 4, 2026. According to the company, regulatory filings in these regions are now underway to enable commercial rollout.

What commercial impact does the AI software announcement have for BDMD shareholders?

The announcement aims to accelerate Baird Medical's commercial roadmap by enabling an integrated interventional ecosystem. According to the company, the technology addresses rising global demand for intelligent, minimally invasive surgical solutions.